| Code | CSB-RA011671MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to Adakitug, designed to specifically target CXCL8 (also known as interleukin-8 or IL-8), a potent chemokine that plays a critical role in inflammatory responses and immune cell recruitment. CXCL8 is primarily secreted by macrophages, epithelial cells, and endothelial cells in response to inflammatory stimuli, where it functions as a powerful chemoattractant for neutrophils and other granulocytes. Dysregulated CXCL8 expression has been implicated in numerous pathological conditions, including chronic inflammatory diseases, acute respiratory distress syndrome, rheumatoid arthritis, inflammatory bowel disease, and various cancers where it promotes tumor progression, angiogenesis, and metastasis.
Adakitug is a humanized monoclonal antibody that has been investigated for its therapeutic potential in neutralizing CXCL8 activity. This biosimilar provides researchers with a valuable tool for investigating CXCL8-mediated signaling pathways, exploring its role in disease pathogenesis, and evaluating potential therapeutic interventions targeting the CXCL8 axis in preclinical models of inflammation and cancer.
There are currently no reviews for this product.